<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03821</article-id><article-id pub-id-type="doi">10.7554/eLife.03821</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>HIV-1 DNA predicts disease progression and post-treatment virological control</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-15974"><name><surname>Williams</surname><given-names>James P</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15975"><name><surname>Hurst</surname><given-names>Jacob</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18419"><name><surname>Stöhr</surname><given-names>Wolfgang</given-names></name><aff><addr-line><named-content content-type="department">MRC Clinical Trials Unit</named-content></addr-line>, <institution>Institute of Clinical Trials and Methodology, University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15977"><name><surname>Robinson</surname><given-names>Nicola</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15978"><name><surname>Brown</surname><given-names>Helen</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15979"><name><surname>Fisher</surname><given-names>Martin</given-names></name><aff><addr-line><named-content content-type="department">Sexual Health and HIV</named-content></addr-line>, <institution>Brighton and Sussex University Hospitals</institution>, <addr-line><named-content content-type="city">Brighton</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15980"><name><surname>Kinloch</surname><given-names>Sabine</given-names></name><aff><addr-line><named-content content-type="department">Division of Infection and Immunity, School for Life Sciences</named-content></addr-line>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15981"><name><surname>Cooper</surname><given-names>David</given-names></name><aff><institution>St Vincent's Centre for Applied Medical Research</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15982"><name><surname>Schechter</surname><given-names>Mauro</given-names></name><aff><addr-line><named-content content-type="department">Hospital Escola São Francisco de Assis</named-content></addr-line>, <institution>Universidade Federal do Rio de Janeiro</institution>, <addr-line><named-content content-type="city">Rio de Janeiro</named-content></addr-line>, <country>Brazil</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15983"><name><surname>Tambussi</surname><given-names>Giuseppe</given-names></name><aff><addr-line><named-content content-type="department">Department of Infectious Diseases</named-content></addr-line>, <institution>Ospedale San Raffaele</institution>, <addr-line><named-content content-type="city">Milan</named-content></addr-line>, <country>Italy</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15984"><name><surname>Fidler</surname><given-names>Sarah</given-names></name><aff><addr-line><named-content content-type="department">Division of Medicine</named-content></addr-line>, <institution>Wright Fleming Institute, Imperial College</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-6981"><name><surname>Carrington</surname><given-names>Mary</given-names></name><aff><addr-line><named-content content-type="department">Cancer and Inflammation Program, Laboratory of Experimental Immunology</named-content></addr-line>, <institution>Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research</institution>, <addr-line><named-content content-type="city">Frederick</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15985"><name><surname>Babiker</surname><given-names>Abdel</given-names></name><aff><addr-line><named-content content-type="department">MRC Clinical Trials Unit</named-content></addr-line>, <institution>Institute of Clinical Trials and Methodology, University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15986"><name><surname>Weber</surname><given-names>Jonathan</given-names></name><aff><addr-line><named-content content-type="department">Division of Medicine</named-content></addr-line>, <institution>Wright Fleming Institute, Imperial College</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15987"><name><surname>Koelsch</surname><given-names>Kersten K</given-names></name><aff><institution>St Vincent's Centre for Applied Medical Research</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15988"><name><surname>Kelleher</surname><given-names>Anthony D</given-names></name><aff><institution>St Vincent's Centre for Applied Medical Research</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15989"><name><surname>Phillips</surname><given-names>Rodney E</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6591"><name><surname>Frater</surname><given-names>John</given-names></name><aff><addr-line><named-content content-type="department">Nuffield Department of Clinical Medicine</named-content></addr-line>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country><email>john.frater@ndm.ox.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib><on-behalf-of>on behalf of the SPARTAC Trial Investigators</on-behalf-of></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-12045"><name><surname>Abdool Karim</surname><given-names>Quarraisha</given-names></name><role>Reviewing editor</role><aff><institution>University of KwaZulu Natal</institution>, <country>South Africa</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>09</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e03821</elocation-id><supplementary-material><ext-link xlink:href="elife-03821-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>28</day><month>06</month><year>2014</year></date><date date-type="accepted"><day>04</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Williams et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Williams et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The SPARTAC trial was approved by the following authorities: Medicines and Healthcare products Regulatory Agency (UK), Ministry of Health (Brazil), Irish Medicines Board (Ireland), Medicines Control Council (South Africa), and The Uganda National Council for Science and Technology (Uganda). It was also approved by the following ethics committees in the participating countries: Central London Research Ethics Committee (UK), Hospital Universitário Clementino Fraga Filho Ethics in Research Committee (Brazil), Clinical Research and Ethics Committee of Hospital Clinic in the province of Barcelona, Spain, The Adelaide and Meath Hospital Research Ethics Committee (Ireland), University of Witwatersrand Human Research Ethics Committee, University of Kwazulu-Natal Research Ethics Committee and University of Cape Town Research Ethics Committee (South Africa), Uganda Virus Research Institute Science and ethics committee (Uganda), The Prince Charles Hospital Human Research Ethics Committee and St Vincent's Hospital Human Research Ethics Committee (Australia), and the National Institute for Infectious Diseases Lazzaro Spallanzani, Institute Hospital and the Medical Research Ethics Committee, and the ethical committee Of the Central Foundation of San Raffaele, MonteTabor (Italy). All participants signed a written informed consent.</p></fn></fn-group></back></article>